Injury RecoveryIntermediate

Injury Recovery Stack: BPC-157 + TB-500

Est. monthly cost£120

Overview

A comprehensive soft tissue and connective tissue recovery protocol combining BPC-157 and TB-500 — the most popular peptide stack in the recovery space. The two peptides have complementary mechanisms, with BPC-157 being particularly effective for localised tissue repair and gut healing, while TB-500 provides broader systemic anti-inflammatory and repair signalling. Together they represent the most researched off-label recovery stack available.

Peptide Stack

PeptideDosageFrequencyTimingDurationNotes
Once dailyCan also be taken orally in capsule form for gut-related issues, though bioavailability differs.
Twice weekly (split total dose)Reduce to once weekly after 6-week loading phase.

Cycle Overview

Loading phase (weeks 1–6): BPC-157 250–500 mcg/day + TB-500 2.5 mg twice weekly. Maintenance phase (weeks 7–12): BPC-157 250 mcg/day + TB-500 2 mg once weekly. Standard cycle 8–12 weeks depending on injury severity. May repeat after 4-week break if needed.

Stacking Notes

BPC-157 and TB-500 work through different but complementary pathways. BPC-157 targets the NO system and local tissue signalling; TB-500 works systemically via actin modulation and anti-inflammatory cytokine suppression. No known negative interactions. Both can be drawn up and injected separately at the same session if using different sites.

Recommended Bloodwork

C-reactive protein (CRP) — inflammatory markerFull blood countLiver function testsBaseline imaging of injury site before/after (MRI or ultrasound where possible)

Warnings

For research purposes only — not medical advice. Always seek medical diagnosis before self-treating any injury. These peptides are not licensed medicines. Avoid using this stack as a substitute for physiotherapy and rehabilitation. Monitor for unusual lumps, swelling, or changes at injection sites. Users with a personal or family history of cancer should avoid angiogenic peptides.

Related Protocols

Last reviewed: Reviewed by: [email protected]